Dr. John Webb

Excellent Early Experience Reported With Edwards SAPIEN 3 Transcatheter Valve by St. Paul's Doctor John Webb

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that the first data on its most advanced commercially available transcatheter aortic heart valve, the Edwards SAPIEN 3 valve, were presented in a late-breaking clinical trial session at EuroPCR 2014 by John Webb, M.D., director of interventional cardiology and cardiac catheterization laboratories at St. Paul's Hospital, Vancouver, and professor of cardiology at the University of British Columbia.

St. Paul's Hospital's Dr. Webb and Dr. Cheung comment on COSIRA Study

Neovasc Inc. (TSXV: NVC) today reported that final data from its COSIRA trial assessing the efficacy and safety of the Neovasc ReducerTM, a novel percutaneous device for the treatment of refractory angina, was presented on March 29, 2014 in a Featured Clinical Research Presentation at ACC.14, the American College of Cardiology 63rd Annual Scientific Session & Expo.

St. Paul's Doctor receives 2014 LifeSciences British Columbia Award

LifeSciences BC is pleased to announce the recipients of the 2014 LifeSciences British Columbia Awards. These awards are presented annually to recognize individuals and companies that have made significant contributions to the development of B.C.’s life sciences industry. The 2014 award winners are:

Innovation & Achievement Award
Dr. John Webb, Director, Centre for Heart Valve Innovation, St. Paul’s Hospital

Subscribe to RSS - Dr. John Webb